viewMedlab Clinical Ltd

Medlab Clinical in trading halt ahead of NanaBis™ cancer trial results

The NanaBis™ study seeks to recruit 2,000 Australian patients via medical or hospital settings to provide intervention data over a 12-month period.

Medlab Clinical Ltd - Medlab Clinical in trading halt ahead of NanaBis™ cancer trial results
Medlab is developing protocols for a phase three trial in Australia and the US

Medlab Clinical Ltd (ASX:MDC) is in a trading halt pending an announcement on the release of results from the NanaBis™ advanced cancer pain trial conducted at Royal North Shore Hospital in Sydney, Australia.

The trading halt will remain in place until the beginning of ASX trade on Monday, March 9, 2020, or when an announcement is released to the market, whichever occurs earliest.

Shares in the company, which has a market cap of approximately $53.6 million, last traded at 22.5 cents.

NanaBis™ study launch 

Medlab officially launched the NanaBis™ observational study in February which aims to provide evidence that is based on real-world data for safety, tolerability, use and potential adverse events as well as potential impacts on the patient while being prescribed other medicines.

Medlab chief executive officer Dr Sean Hall said: “Medlab will be working closely with healthcare professionals to provide educational tools to better understand NanaBis™ as a treatment option for patients living with chronic pain.

“Participating patients will have access to medical cannabis at a significantly reduced price.”

Doctors will also be compensated for their participation in the study on a monthly, per-patient basis.

Quick facts: Medlab Clinical Ltd

Price: 0.215 AUD

Market: ASX
Market Cap: $50.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...



Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read